Fidelis Capital Partners LLC Grows Stake in Edwards Lifesciences Co. (NYSE:EW)

Fidelis Capital Partners LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 10.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,571 shares of the medical research company’s stock after buying an additional 507 shares during the period. Fidelis Capital Partners LLC’s holdings in Edwards Lifesciences were worth $515,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after acquiring an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Edwards Lifesciences by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after purchasing an additional 809,605 shares in the last quarter. Wellington Management Group LLP lifted its position in Edwards Lifesciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after purchasing an additional 393,109 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after buying an additional 2,390,137 shares in the last quarter. Finally, Sands Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 34.6% in the 4th quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock worth $465,407,000 after buying an additional 1,567,526 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock worth $1,218,138 over the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.6 %

NYSE EW opened at $66.83 on Monday. The stock has a market cap of $40.27 billion, a P/E ratio of 28.81, a price-to-earnings-growth ratio of 2.85 and a beta of 1.13. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a 50 day simple moving average of $69.89 and a two-hundred day simple moving average of $82.80. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter last year, the firm posted $0.66 earnings per share. The firm’s revenue was up 6.7% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on EW. Baird R W downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Truist Financial cut their price objective on Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating for the company in a report on Friday, September 13th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Finally, Citigroup lifted their price target on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $79.82.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.